Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a research study looking at the effect of 5-Hydroxy Tryptophan (5-HTP) on urine excretion of 5-Hydroxyindolacetic acid (5-HIAA). 5-HTP is a common over the counter product that is sold in natural food stores and via the Internet. Increased levels of 5-HIAA in the urine can be found in a specific type of cancer, called carcinoid tumor. This study will examine the effect of oral 5-HTP intake on 5-HIAA excretion. Understanding this effect may help to determine which tests should be done in a patient with increased 5-HIAA excretion who’s also taking 5-HTP.
| Condition | Intervention | Phase |
|---|---|---|
|
Carcinoid Tumors Neuroendocrine Tumors |
Drug: 5-Hydroxy-Tryptamine |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Diagnostic |
| Official Title: | Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion |
- Urinary excretion of 5-HIAA
- Plasma Chromogranin A
- Side effects
| Estimated Enrollment: | 8 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | September 2005 |
5-HTP is a common over the counter product that is sold in natural food stores and via the Internet. It is claimed to improve sleep problems, depression, anxiety, compulsive disorders, restless leg syndrome, migraines, fibromyalgia, and low pain threshold.Increased levels of 5-HIAA in the urine can be a of a specific type of cancer, called carcinoid tumor. Urinary 5-HIAA levels can also be increased by a number of food products and drugs. Oral 5-HTP is not known as a cause of elevation of 5-HIAA in urine. However, recent information suggests that 5-HTP may cause an increase.
In this study we examine the effect of oral 5-HTP intake (100 mg at bedtime for 10 days) on 5-HIAA excretion in the urine, following a prospective, double-blind placebo-controlled study design.
Understanding this effect may help to determine which tests should be done in a patient with increased 5-HIAA excretion who’s also taking 5-HTP.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 18 years and older
- in good health
Exclusion Criteria:
- Pregnancy
- Intake of drugs that affect 5-HIAA excretion in urine
- Anti-depressants
- Participation in other studies
Contacts and Locations| Canada, Ontario | |
| St. Joseph's Health Care | |
| London, Ontario, Canada, N6A 4V2 | |
| Principal Investigator: | Stan HM Van Uum, MD, PhD | University of Western Ontario, Canada |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00227136 History of Changes |
| Other Study ID Numbers: | 5-HTPSVU |
| Study First Received: | September 23, 2005 |
| Last Updated: | July 11, 2006 |
| Health Authority: | Canada: Health Canada |
Keywords provided by University of Western Ontario, Canada:
|
5Hydroxytryptamine Chromogranin A 5HIAA carcinoid |
Additional relevant MeSH terms:
|
Carcinoid Tumor Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial |
Neoplasms, Nerve Tissue Serotonin Serotonin Receptor Agonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 19, 2013